NIMIUM Therapeutics and Paraza Pharma form partnership to develop new drugs to treat cardiometabolic disease (CMD), obesity and type 2 diabetes
Category: Small Molecules
Posted on Wednesday, July 21, 2021 10:49 AM
Innovative partnership focuses on early stage development of activators for a glucose detoxifying enzyme called glycerol-3-phosphate phosphatase (G3PP)
MONTREAL, Canada I July 20, 2021 I NIMIUM Therapeutic (www.nimium.ca), a Montreal biotech, has formed a partnership with Paraza Pharma (www.parazapharma.com) to develop a new treatment for cardiometabolic diseases (CMD). Treatment aims to prevent and reverse the unwanted effects of excess sugar and calorie intake and to promote healthier aging. The partnership will focus on the early development of glycerol-3-phosphate phosphatase (G3PP) activators.
The G3PP enzyme was discovered in mammalian cells by the laboratory of Professor Marc Prentki at the Research Center of the Center Hospitalier de l’Université de Montréal (CRCHUM), which demonstrated the central role of the enzyme in the reduction of side effects of excessive calorie intake. This breakthrough preclinical research have shown that activation of G3PP treats multiple complications related to metabolic syndrome such as obesity, type 2 diabetes and cardiovascular disease. Additionally, in vivo experiments have shown that activating G3PP contributes to healthier aging. NIMIUM has access to G3PP activator hits identified by adMare BioInnovations, who collaborated with Dr. Prentki to translate his research into potential commercial applications.
Under the agreement, Paraza Pharma will apply its expertise in medicinal chemistry, biology and integrated drug discovery to develop flagship compounds activating G3PP, and NIMIUM will provide in vitro and in vivo proof of concept experiments on animals.
“This partnership is focused on providing a potentially revolutionary therapy for cardiometabolic diseases,” said Dr. Arshad Siddiqui, Founder and CEO of Paraza Pharma. “Paraza Pharma has the expertise and the capacity to translate this important research into a new therapy that could help patients.”
Cardiometabolic diseases are the leading cause of death worldwide. They include cardiovascular disease, type 2 diabetes, chronic kidney disease, high cholesterol, hypertriglyceridemia, hypertension, and nonalcoholic fatty liver disease. Currently, each of these conditions requires separate treatments. Dr. Prentki’s research indicates that G3PP, through its actions on glucose and fat metabolism, has the potential to treat them holistically.
Philippe Walker, CEO of NIMIUM Therapeutics, said: “Cardiometabolic disease is a major cause of illness and death. New approaches are needed to deal with this growing health crisis. If successful, it could transform the way these diseases are treated.
About NIMIUM Therapeutics
NIMIUM Therapeutics is a Montreal-based biotech focused on the development of innovative therapeutics to treat cardiometabolic diseases (CMD). The research is based on glycerol-3-phosphate phosphatase (G3PP), an enzyme that plays a central role in the metabolism of glucose, lipids and energy in humans. NIMIUM has partnerships with adMare BioInnovations, a Canadian organization that provides expertise, infrastructure and capital to help build life science businesses; and with Paraza Pharma, a leading contract research organization specializing in drug development. NIMIUM received funding from Investissement Québec.
About Paraza Pharma
Paraza Pharma, a company based in Montreal, Canada and Cambridge, Massachusetts, USA, is an integrated preclinical drug discovery organization focused on excellence in science and innovation.
SOURCE: Paraza Pharma